This is a Phase I, single center, randomized, double-blind, placebo-controlled single ascending oral dose study to assess the safety, tolerability and pharmacokinetics of AZD7268 in healthy Japanese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
56
Research Site
Gelndale, California, United States
To asses the safety nature and incidence of adverse events, blood pressure, pulse rate, body temperature, physical examination, laboratory assessments (clinical chemistry, hematology, and urinalysis parameters), effects on ECG parameters, EEG recordings,
Time frame: From screening period to follow-up, 44 days (maiximum).
To characterize the pharmacokinetics of AZD7268 and its metabolite(s) in plasma and urine.
Time frame: Blood and urine sampling from pre-dose until 72 hrs post dose.
To collect and store DNA for future exploratory research
Time frame: One blood sampling after randomisation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.